Emerald Advisers LLC Buys New Stake in CeriBell (NASDAQ:CBLL)

Emerald Advisers LLC purchased a new stake in shares of CeriBell (NASDAQ:CBLL) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 120,805 shares of the company’s stock, valued at approximately $3,126,000. Emerald Advisers LLC owned 0.34% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Rhumbline Advisers acquired a new position in shares of CeriBell during the 4th quarter valued at $320,000. Vanguard Group Inc. acquired a new position in shares of CeriBell during the 4th quarter valued at $18,015,000. Charles Schwab Investment Management Inc. acquired a new position in shares of CeriBell during the 4th quarter valued at $2,500,000. Bank of New York Mellon Corp acquired a new position in shares of CeriBell during the 4th quarter valued at $628,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of CeriBell during the 4th quarter valued at $47,000.

CeriBell Price Performance

CBLL opened at $20.42 on Monday. The stock’s fifty day moving average is $22.35. CeriBell has a fifty-two week low of $18.69 and a fifty-two week high of $32.75.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. Equities research analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CBLL shares. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. TD Cowen raised their price objective on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.60.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.